S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
NASDAQ:MLAB

Mesa Laboratories (MLAB) Stock Forecast, Price & News

$113.00
-4.00 (-3.42%)
(As of 09/21/2023 ET)
Compare
Today's Range
$111.48
$118.15
50-Day Range
$113.00
$143.36
52-Week Range
$111.48
$206.36
Volume
39,617 shs
Average Volume
31,830 shs
Market Capitalization
$607.94 million
P/E Ratio
342.43
Dividend Yield
0.57%
Price Target
$166.00

Mesa Laboratories MarketRank™ Forecast

Analyst Rating
0.00 Rating Score
Upside/​Downside
46.9% Upside
$166.00 Price Target
Short Interest
Bearish
6.73% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.85mentions of Mesa Laboratories in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$779,340 Sold Last Quarter
Proj. Earnings Growth
-8.64%
From $5.67 to $5.18 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.28 out of 5 stars

Medical Sector

933rd out of 965 stocks

Process Control Instruments Industry

11th out of 11 stocks


MLAB stock logo

About Mesa Laboratories (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

MLAB Price History

MLAB Stock News Headlines

MLAB: Lowering target price to $102.00
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Here’s Why Mesa Laboratories (MLAB) Declined in Q2
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Mesa Labs (MLAB) Surpasses Q1 Earnings Estimates
Mesa Laboratories's Earnings Outlook
See More Headlines
Receive MLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesa Laboratories and its competitors with MarketBeat's FREE daily newsletter.

MLAB Company Calendar

Last Earnings
8/03/2023
Ex-Dividend for 9/15 Dividend
8/30/2023
Dividend Payable
9/15/2023
Today
9/22/2023
Next Earnings (Confirmed)
11/06/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Process control instruments
Sub-Industry
Electronic Equipment & Instruments
Sector
Medical
Current Symbol
NASDAQ:MLAB
CUSIP
59064R10
Employees
698
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$166.00
High Stock Price Forecast
$166.00
Low Stock Price Forecast
$166.00
Forecasted Upside/Downside
+46.9%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$930,000.00
Pretax Margin
1.86%

Debt

Sales & Book Value

Annual Sales
$219.08 million
Cash Flow
$11.48 per share
Book Value
$73.60 per share

Miscellaneous

Free Float
5,104,000
Market Cap
$607.94 million
Optionable
Not Optionable
Beta
0.72
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Gary M. OwensMr. Gary M. Owens (Age 55)
    CEO, Pres & Director
    Comp: $1.02M
  • Mr. John V. SakysMr. John V. Sakys (Age 54)
    VP, CFO & Chief Accounting Officer
    Comp: $551.4k
  • Mr. Brian David ArchboldMr. Brian David Archbold (Age 47)
    Sr. VP of Continuous Improvement
    Comp: $485.59k













MLAB Stock - Frequently Asked Questions

What is Mesa Laboratories' stock price forecast for 2023?

0 equities research analysts have issued 12-month price objectives for Mesa Laboratories' shares. Their MLAB share price forecasts range from $166.00 to $166.00. On average, they anticipate the company's stock price to reach $166.00 in the next twelve months. This suggests a possible upside of 46.9% from the stock's current price.
View analysts price targets for MLAB
or view top-rated stocks among Wall Street analysts.

How have MLAB shares performed in 2023?

Mesa Laboratories' stock was trading at $166.21 on January 1st, 2023. Since then, MLAB stock has decreased by 32.0% and is now trading at $113.00.
View the best growth stocks for 2023 here
.

When is Mesa Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our MLAB earnings forecast
.

How were Mesa Laboratories' earnings last quarter?

Mesa Laboratories, Inc. (NASDAQ:MLAB) posted its quarterly earnings results on Thursday, August, 3rd. The medical instruments supplier reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.09. The medical instruments supplier had revenue of $50.65 million for the quarter, compared to analyst estimates of $51.85 million. Mesa Laboratories had a net margin of 0.83% and a trailing twelve-month return on equity of 9.36%.

How often does Mesa Laboratories pay dividends? What is the dividend yield for Mesa Laboratories?

Mesa Laboratories announced a quarterly dividend on Wednesday, July 5th. Shareholders of record on Thursday, August 31st will be paid a dividend of $0.16 per share on Friday, September 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date is Wednesday, August 30th.
Read our dividend analysis for MLAB
.

What ETFs hold Mesa Laboratories' stock?

ETFs with the largest weight of Mesa Laboratories (NASDAQ:MLAB) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS).Motley Fool Small-Cap Growth ETF (TMFS).

Is Mesa Laboratories a good dividend stock?

Mesa Laboratories (NASDAQ:MLAB) pays an annual dividend of $0.64 per share and currently has a dividend yield of 0.55%. The dividend payout ratio is 193.95%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MLAB will have a dividend payout ratio of 12.36% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MLAB.

What is Gary Owens' approval rating as Mesa Laboratories' CEO?

5 employees have rated Mesa Laboratories Chief Executive Officer Gary Owens on Glassdoor.com. Gary Owens has an approval rating of 51% among the company's employees. This puts Gary Owens in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mesa Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesa Laboratories investors own include NVIDIA (NVDA), Verizon Communications (VZ), Intel (INTC), Alibaba Group (BABA), Altria Group (MO), Micron Technology (MU), Exxon Mobil (XOM), AbbVie (ABBV), Advanced Micro Devices (AMD) and Becton, Dickinson and Company (BDX).

What is Mesa Laboratories' stock symbol?

Mesa Laboratories trades on the NASDAQ under the ticker symbol "MLAB."

Who are Mesa Laboratories' major shareholders?

Mesa Laboratories' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.17%), Conestoga Capital Advisors LLC (10.71%), Ranger Investment Management L.P. (4.33%), Geneva Capital Management LLC (3.56%), State Street Corp (3.35%) and Royce & Associates LP (2.97%). Insiders that own company stock include Brian David Archbold, David M Kelly, Evan Guillemin, Gary M Owens, Gregory Dinoia, John Bradley Schmieder, John James Sullivan, John Sakys and Shannon Hall.
View institutional ownership trends
.

How do I buy shares of Mesa Laboratories?

Shares of MLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesa Laboratories' stock price today?

One share of MLAB stock can currently be purchased for approximately $113.00.

How much money does Mesa Laboratories make?

Mesa Laboratories (NASDAQ:MLAB) has a market capitalization of $607.94 million and generates $219.08 million in revenue each year. The medical instruments supplier earns $930,000.00 in net income (profit) each year or $0.33 on an earnings per share basis.

How many employees does Mesa Laboratories have?

The company employs 698 workers across the globe.

How can I contact Mesa Laboratories?

Mesa Laboratories' mailing address is 12100 W 6TH AVE, LAKEWOOD CO, 80228. The official website for the company is www.mesalabs.com. The medical instruments supplier can be reached via phone at (303) 987-8000, via email at investorrelations@mesalabs.com, or via fax at 303-987-8989.

This page (NASDAQ:MLAB) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -